Rethinking Treatment Goals in Psoriasis: Leveraging IL-17 Inhibitors to Move Beyond Skin Clearance Toward PsA Prevention - Episode 9
Long-Term IL-17 Data and Real-World Comparisons: Preventing PsA in Psoriasis
In this episode, the panelists discuss long-term IL-17 data and real-world evidence on preventing psoriatic arthritis (PsA) in patients with psoriasis. They highlight results from the five-year secukinumab study presented at ACR Convergence 2025, which showed that 97.9% of psoriasis patients treated with secukinumab did not develop PsA over the study period. The experts view this as compelling evidence supporting the disease-modifying potential of IL-17 inhibition. They also reference real-world data which compared PsA incidence across biologic classes and found that IL-17 and IL-23 inhibitors were associated with a lower PsA risk than TNF inhibitors or methotrexate. The panelists emphasize that IL-17 inhibitors not only achieve durable skin clearance but also offer a favorable safety profile and reduced need for lab monitoring. Overall, they interpret these findings as reinforcing the role of targeted IL-17 blockade in preventing PsA progression in high-risk psoriasis patients.
In this episode, the panelists discuss long-term IL-17 data and real-world evidence on preventing psoriatic arthritis (PsA) in patients with psoriasis. They highlight results from the five-year secukinumab study presented at ACR Convergence 2025, which showed that 97.9% of psoriasis patients treated with secukinumab did not develop PsA over the study period. The experts view this as compelling evidence supporting the disease-modifying potential of IL-17 inhibition. They also reference real-world data which compared PsA incidence across biologic classes and found that IL-17 and IL-23 inhibitors were associated with a lower PsA risk than TNF inhibitors or methotrexate. The panelists emphasize that IL-17 inhibitors not only achieve durable skin clearance but also offer a favorable safety profile and reduced need for lab monitoring. Overall, they interpret these findings as reinforcing the role of targeted IL-17 blockade in preventing PsA progression in high-risk psoriasis patients.
